Gil Epstein, MD
Ophthalmic Plastic and Reconstructive Surgery · Plantation, FLNPI 1679575351
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.8%), ownership interests and education — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by US Retina LLC at 41.8% of the total. Reporting peaked in 2022 at $1,391 and has fallen 81.0% since, to $265 in 2025.
Across 93 payments — averaging $49.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$2K
- Amgen$979
- AbbVie$474
- Bausch & Lomb, A Division Of Bausch Health US, LLC$234
- Bausch & Lomb Americas Inc.$143
- Biotissue Holdings Inc.$140
- plus $712 from 14 others
What the payments were for
- Food & beverage$2,56956%
- Education$1122%
- Ownership interest$1,92642%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 5 | $1,926 |
| Amgen(2 entities) | 41 | $979 |
| AbbVie(2 entities) | 15 | $474 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $234 |
| Bausch & Lomb Americas Inc. | 2 | $143 |
| Biotissue Holdings Inc. | 3 | $140 |
| Genentech USA, Inc. | 1 | $138 |
| Alcon | 1 | $122 |
| Regeneron Healthcare Solutions, Inc. | 5 | $96 |
| Mallinckrodt Hospital Products Inc. | 1 | $88 |
| Merz Pharmaceuticals, LLC | 2 | $43 |
| Dompe US, Inc. | 2 | $42 |
| Sun Pharmaceutical Industries Inc. | 2 | $41 |
| Ocular Therapeutix, Inc. | 2 | $33 |
| Kala Pharmaceuticals, Inc. | 2 | $30 |
| Coherus Oncology, Inc. | 1 | $18 |
| Harrow Eye, LLC | 1 | $16 |
| Aerie Pharmaceuticals, Inc. | 1 | $15 |
| Tarsus Pharmaceuticals, Inc. | 1 | $15 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$399
- VYZULTA$229
- Erivedge$138
- Hydrus Microstent$122
- VUITY$101
How this compares
$4,607 in reported general payments places this provider in the 75th percentile of 37 ophthalmic plastic and reconstructive surgery providers in Florida.
See all ophthalmic plastic and reconstructive surgery providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 11 | $9,892 |
| BotoxOnabotulinumtoxina | 11 | $7,084 |
| Prednisolone Acetate | 63 | $1,858 |
| ErythromycinErythromycin Base | 156 | $1,686 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 32 | $1,501 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 88 | $1,012 |
| Methylprednisolone | 29 | $192 |
| Ofloxacin | 12 | $144 |
| Doxycycline Hyclate | 13 | $137 |
| Cephalexin | 18 | $119 |
| Latanoprost | 17 | $100 |
| Hydrochlorothiazide | 12 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Botox | $474 | $16,97622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 37 ophthalmic plastic and reconstructive surgery providers in Florida.
Other ophthalmic plastic and reconstructive surgery in Plantation
- Aliza EpsteinPlantation$4K
- Dan GeorgescuPlantation$2K
- John FezzaVenice$3.6M
- Wendy LeeMiami$616K
- Jennifer MurdockMiami$316K
- Ana VictoriaMiami$130K
- Keshini ParbhuWindermere$102K
- Sara WesterMiami$78K
- Robert ApplebaumLakeland$39K
- Yasaman MohadjerSt Petersburg$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.